ANAVEX LIFE SCIENCES CORP (AVXL) Stock Overview
USA - NASDAQ:AVXL - US0327973006 - Common Stock
AVXL Key Statistics, Chart & Performance
The current stock price of AVXL is 8.615 USD. In the past month the price decreased by -0.52%. In the past year, price increased by 64.41%.
AVXL Latest News, Press Relases and Analysis
AVXL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About AVXL
Company Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Company Info
ANAVEX LIFE SCIENCES CORP
630 5Th Avenue, 20Th Floor
New York City NEW YORK 10019 US
CEO: Christopher Missling
Employees: 42
Phone: 18446893939
ANAVEX LIFE SCIENCES CORP / AVXL FAQ
Can you describe the business of ANAVEX LIFE SCIENCES CORP?
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
What is the stock price of ANAVEX LIFE SCIENCES CORP today?
The current stock price of AVXL is 8.615 USD. The price decreased by -1.43% in the last trading session.
Does AVXL stock pay dividends?
AVXL does not pay a dividend.
How is the ChartMill rating for ANAVEX LIFE SCIENCES CORP?
AVXL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists AVXL stock?
AVXL stock is listed on the Nasdaq exchange.
What is the employee count for AVXL stock?
ANAVEX LIFE SCIENCES CORP (AVXL) currently has 42 employees.
What is the ownership structure of ANAVEX LIFE SCIENCES CORP (AVXL)?
You can find the ownership structure of ANAVEX LIFE SCIENCES CORP (AVXL) on the Ownership tab.
AVXL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AVXL. When comparing the yearly performance of all stocks, AVXL is one of the better performing stocks in the market, outperforming 78.87% of all stocks.
AVXL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVXL. AVXL has a great financial health rating, but its profitability evaluates not so good.
AVXL Financial Highlights
Over the last trailing twelve months AVXL reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS decreased by -14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.03% | ||
| ROE | -52.96% | ||
| Debt/Equity | 0 |
AVXL Forecast & Estimates
9 analysts have analysed AVXL and the average price target is 35.02 USD. This implies a price increase of 306.5% is expected in the next year compared to the current price of 8.615.